Enhanced Care Management and Continuous Monitoring With Alio Smart Patch in Adult Cancer Patients Receiving Chemotherapy or Immunotherapy at Risk of Febrile Neutropenia

What this Trial Is About

This research aims to evaluate a remote monitoring program designed for adult cancer patients receiving chemotherapy or immunotherapy, particularly those at moderate or high risk of febrile neutropenia or related complications. The study focuses on early detection and management of treatment side effects by continuously tracking vital signs and blood levels to reduce emergency visits and hospital admissions. The program uses advanced wearable technology to provide real-time physiological and biochemical data to healthcare providers. Participants will wear the Alio Smart Patch, a non-invasive biosensor that continuously measures vital signs, hematologic, and electrolyte data. They will also use continuous glucose monitors to track glucose levels. This data is remotely monitored by clinical staff from Quantify Remote Care, who will contact participants promptly if signs of side effects or complications arise. The program also offers dietary and mental health support as needed. The study period lasts up to 13 weeks, during which participants receive continuous monitoring and support. Throughout the study, researchers will assess participant compliance with wearing the devices, usability and comfort, and overall satisfaction. They will also track clinical outcomes such as the identification of febrile neutropenia symptoms and the effectiveness of early detection in reducing emergency care visits. Data collected will support better clinical decisions while participants continue their regular cancer treatment. The total participation duration extends up to 13 weeks from enrollment, with close monitoring by the study team.

ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy